三生国健：与辉瑞就707项目签署的许可协议正式生效

Core Insights - The licensing agreement for Project 707 between the company and Pfizer has officially come into effect [1] - Pfizer will exclusively develop and commercialize the project in mainland China, with total payments not exceeding $150 million in non-refundable option and exercise fees [1] - The agreement includes a "Mainland China Option Agreement," expanding the licensing area to a global scale upon activation [1] - The profit-sharing ratio between the company and Shenyang Sansheng is set at 30% to 70% [1] - This transaction is classified as a related party transaction and does not constitute a major asset restructuring [1] - The deal is expected to advance the global development and commercialization of Project 707, enhancing the company's product accessibility and recognition in international markets [1]